Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

@article{Chawla2006UpdatedRO,
  title={Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.},
  author={Sant P. Chawla and Anthony William Tolcher and Arthur P. Staddon and Scott Michael Schuetze and Gina Z D'Amato and Jean-Yves Blay and Kamalesh Kumar Sankhala and Susan S. Daly and V. Rivera and George Daniel Demetri},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={9505}
}
9505 Background: AP23573 is an mTOR inhibitor that has shown anti-tumor activity in phase 1 clinical trials, particularly in patients with advanced sarcomas. Given this observation, this phase 2 trial was undertaken to assess further the efficacy and safety of AP23573 across various sarcoma subtypes. METHODS Advanced sarcoma pts, with no restrictions on prior therapies, were enrolled into 4 cohorts based on histologic subtype, in a phase 2 trial with Simon's 2-stage design. AP23573 (12.5 mg… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Similar Papers

Loading similar papers…